Nvidia takes a stake in Doctolib, one of France’s leading digital health companies. Announced in Paris by the American group’s CEO, Jensen Huang, the minority investment is to be accompanied by technical cooperation on artificial intelligence. For Doctolib, the goal is to accelerate the development of its own models and prepare new services for patients.
The American chip and AI technology giant is investing in Doctolib, a French platform specializing in medical appointment booking and digital health services. Jensen Huang announced the deal during his visit to Paris, as part of a series of initiatives focused on France’s artificial intelligence ecosystem.
The amount of the investment, the valuation agreed upon, and the exact stake acquired by Nvidia have not been made public. Doctolib says, however, that the American company will take a minority stake. The deal therefore does not amount to a takeover; rather, it establishes a partnership between two players with complementary expertise, one specializing in computing infrastructure and the other in online health services.
Nvidia also plans to invest in three other French startups involved in artificial intelligence: Pigment, Genesis AI and Entalpic. This series of deals reflects the American group’s growing interest in European companies capable of transforming their industries through AI.
A financial investment accompanied by a technology partnership
Tools to develop Doctolib’s models
The cooperation between Nvidia and Doctolib is intended to go beyond the financial dimension alone. The American group aims to help the French company train its own artificial intelligence models in Europe. This support could give it access to hardware and technical resources suited to software capable of handling complex requests, particularly in the field of healthcare.
Doctolib has already been using Nvidia technologies for about a year. This closer relationship therefore extends an existing collaboration and is part of the French company’s efforts to strengthen its artificial intelligence capabilities. It plans, in particular, to step up hiring in this field in order to bring together more expertise in research, engineering and product development.
The partnership comes as companies seek to integrate AI into a growing number of activities. Retail, for example, is already exploring the potential of these tools to personalize services and automate certain tasks, as described in this article on the impact of artificial intelligence on the retail industry. In healthcare, the needs are different, but the question remains similar: how to design technologies that are useful, reliable and suited to users’ expectations.
An investment strategy focused on the European ecosystem
Jensen Huang presented Nvidia’s commitment as a contribution to the development of European companies. Asked how Europe could take part in global competition, he said the continent first needed to fully engage in this technological race. He also stressed that his group’s interest in the region had intensified significantly over the past year.
According to the executive, Nvidia has committed around $8 billion to investments in Europe since he announced plans to support the local ecosystem. The deals in France are part of this broader strategy, which combines investments in specialized companies with cooperation on the infrastructure needed to develop AI.
This competition is not limited to chip performance. It also depends on the ability to fund companies, attract researchers and build infrastructure. The prospect of a major artificial intelligence campus in Seine-et-Marne also illustrates France’s ambitions in this area, as reported in this article on the AI campus project in Europe.
An artificial intelligence assistant for patients
Among Doctolib’s projects is an AI assistant designed to support patients. It should be able to answer certain health questions and help users navigate their care journey. The company says the tool is already being used by around 400,000 people in France and plans to make it available to the general public in 2027.
Such a service raises specific issues. The responses provided must be relevant and easy to understand, while directing patients to a healthcare professional when necessary. In a field as sensitive as healthcare, AI cannot replace diagnosis or medical decision-making. Its intended role is instead to serve as an information and support tool, integrated into a broader care pathway.
Doctolib will also need to be vigilant about data protection and the quality of the results produced by its systems. Training models suited to medical needs, as well as evaluating them in a variety of situations, will be crucial to earning the trust of patients and healthcare professionals.
Doctolib’s valuation and the changing technology market
Nvidia’s investment comes after a shareholding transaction carried out a few months earlier. In April, international investors acquired nearly €300 million worth of shares held by employees and long-standing investors. The transaction was based on a valuation of €3.6 billion for Doctolib.
This estimate is below the €5.8 billion valuation the company reached in 2022, a decline of around 38%. It reflects a more demanding environment for technology companies: investors are paying greater attention to profitability and the strength of the business model, rather than just growth in users or revenue.
The valuation agreed upon in April was based on the sale of existing shares. It should therefore not be confused with the amount of Nvidia’s investment, which has not been disclosed. The American group has said neither what percentage of the company is involved nor whether a valuation was attached to its own investment.
Doctolib counts several financial players among its investors, including Eurazeo, Bpifrance, General Atlantic and Accel. The company says it has reached profitability and reports €422 million in annual recurring revenue in 2025. It says its services are used by around 100 million patients and 580,000 healthcare professionals in Europe.
Nvidia and Doctolib at the intersection of healthcare and AI
This deal brings together two rapidly evolving fields: the computing infrastructure needed for artificial intelligence and digital health services. Nvidia, known for its graphics cards and processors widely used in AI systems, is partnering with a company that has extensive access to everyday medical use cases.
The economic momentum in the AI sector is accompanied by massive investment, but also by questions about costs, resources and the reuse of equipment. These issues are explored in this analysis of the billions behind artificial intelligence and its intriguing circular economy. For companies like Doctolib, the ability to develop useful services while controlling costs will be an important factor in their growth.
Computing power remains central to this transformation, but it does not depend exclusively on large data centers. More compact solutions can also support certain specialized applications. The Raspberry Pi 5 and its dedicated AI chip illustrate this diversity of approaches in the article on the role of innovative chips in artificial intelligence.
Finally, the partnership between Nvidia and Doctolib comes at a time when European players are seeking to strengthen their technological autonomy in the face of major American companies. The development of models and solutions designed in Europe is central to this discussion, as also illustrated by Mistral AI’s push to take on the sector’s giants, covered in this article on the French company’s strategy.
